重症COVID-19患者中超过10%存在I型干扰素自身抗体:一项前瞻性多中心研究
这项前瞻性多中心队列研究纳入大巴黎地区11个ICU的925例SARS-CoV-2感染并急性呼吸衰竭的危重患者,检测中和I型IFN-α2、β和/或ω的自身抗体。96例(10.3%)阳性;阳性者入ICU时需更高FiO2(100%(70-100)vs 90%(60-100),p=0.01),其他特征无差异。28天死亡率在阳性与阴性组间无差异(18.7% vs 23.7%,p=0.279)。多因素分析中28天死亡率与年龄(aOR=1.06 [1.04-1.08],p<0.001)、SOFA评分(aOR=1.18 [1.12-1.23],p<0.001)和免疫抑制(aOR=1.82 [1.1-3.0],p=0.02)相关,与自身抗体存在无关(aOR=0.69 [0.38-1.26],p=0.23)。
要点
- 在11个ICU的925例危重COVID-19肺炎患者中,96例(10.3%)检出中和I型IFN-α2、β和/或ω的自身抗体。
- 自身抗体阳性者入ICU时需更高FiO2(100%(70-100)vs 90%(60-100),p=0.01),其余特征与阴性者无差异。
- 28天死亡率自身抗体阳性组18.7% vs 阴性组23.7%,p=0.279,无统计学差异。
- 多因素分析:年龄aOR=1.06 [1.04-1.08],p<0.001;SOFA评分aOR=1.18 [1.12-1.23],p<0.001;免疫抑制aOR=1.82 [1.1-3.0],p=0.02;自身抗体aOR=0.69 [0.38-1.26],p=0.23。
适用人群与场景
- 纳入大巴黎地区11个ICU收治的、经证实SARS-CoV-2感染并急性呼吸衰竭的危重COVID-19患者,共925例。
研究设计与关键结果
- 研究类型:前瞻性多中心队列研究,纳入大巴黎地区11个ICU的925例危重COVID-19肺炎合并急性呼吸衰竭患者。
- 自身抗体(中和I型IFN-α2、β和/或ω)阳性96例(10.3%),阳性与阴性组人口学特征和合并症无差异。
- 入ICU时自身抗体阳性组需更高FiO2(100%(70-100)vs 90%(60-100),p=0.01),其他特征无差异。
- 28天死亡率自身抗体阳性组18.7% vs 阴性组23.7%,p=0.279,无统计学差异。
- 多因素分析:28天死亡率与年龄(aOR=1.06 [1.04-1.08],p<0.001)、SOFA评分(aOR=1.18 [1.12-1.23],p<0.001)、免疫抑制(aOR=1.82 [1.1-3.0],p=0.02)相关,与自身抗体存在无关(aOR=0.69 [0.38-1.26],p=0.23)。
证据类型、等级与局限
- 证据类型:前瞻性多中心队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,明确自身抗体是否影响危重COVID-19患者的表现和结局可能导向特异性治疗干预;本研究显示自身抗体与28天死亡率无关。
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Auto-antibodies (auto-Abs) neutralizing type I interferons (IFN) have been found in about 15% of critical cases COVID-19 pneumonia and less than 1% of mild or asymptomatic cases. Determining whether auto-Abs influence presentation and outcome of critically ill COVID-19 patients could lead to specific therapeutic interventions. Our objectives were to compare the severity at admission and the mortality of patients hospitalized for critical COVID-19 in ICU with versus without auto-Abs.
RESULTS: We conducted a prospective multicentre cohort study including patients admitted in 11 intensive care units (ICUs) from Great Paris area hospitals with proven SARS-CoV-2 infection and acute respiratory failure. 925 critically ill COVID-19 patients were included. Auto-Abs neutralizing type I IFN-α2, β and/or ω were found in 96 patients (10.3%). Demographics and comorbidities did not differ between patients with versus without auto-Abs. At ICU admission, Auto-Abs positive patients required a higher FiO2 (100% (70-100) vs. 90% (60-100), p = 0.01), but were not different in other characteristics. Mortality at day 28 was not different between patients with and without auto-Abs (18.7 vs. 23.7%, p = 0.279). In multivariable analysis, 28-day mortality was associated with age (adjusted odds ratio (aOR) = 1.06 [1.04-1.08], p < 0.001), SOFA score (aOR = 1.18 [1.12-1.23], p < 0.001) and immunosuppression (aOR = 1.82 [1.1-3.0], p = 0.02), but not with the presence of auto-Abs (aOR = 0.69 [0.38-1.26], p = 0.23).
CONCLUSIONS: In ICU patients, auto-Abs against type I IFNs were found in at least 10% of patients with critical COVID-19 pneumonia. They were not associated with day 28 mortality.
参考来源
- Arrestier R, Bastard P, Belmondo T, et al. Auto-antibodies against type I IFNs in > 10% of critically ill COVID-19 patients: a prospective multicentre study. Ann Intensive Care. 2022. PMID: 36586050. doi:10.1186/s13613-022-01095-5
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。